This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: Pyrimidine derivatives as potent and selective A 3 adenosine receptor antagonists

Title Pyrimidine derivatives as potent and selective A 3 adenosine receptor antagonists
Abstract

Two regioisomeric series of diaryl 2- or 4-amidopyrimidines have been synthesized and their adenosine receptor affinities were determined in radioligand binding assays at the four human adenosine receptors (hARs). Some of the ligands prepared herein exhibit remarkable affinities (K(i) < 10 nm) and, most noticeably, the absence of activity at the A(1), A(2A), and A(2B) receptors. The structural determinants that support the affinity and selectivity profiles of the series were highlighted through an integrated computational approach, combining a 3D-QSAR model built on the second generation of GRid INdependent Descriptors (GRIND2) with a novel homology model of the hA(3) receptor. The robustness of the computational model was subsequently evaluated by the design of new derivatives exploring the alkyl substituent of the exocyclic amide group. The synthesis and evaluation of the novel compounds validated the predictive power of the model, exhibiting excellent agreement between predicted and experimental activities.

Apa Reference Yaziji, V., Rodríguez, D., Gutiérrez-de-Terán, H., Coelho, A., Caamaño, O., García-Mera, X., Brea, J., Loza, M. I., Cadavid, M. I., & Sotelo, E. (2010). Pyrimidine Derivatives as Potent and Selective A3Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 54(2), 457–471. 10.1021/jm100843z
Doi 10.1021/jm100843z
Publication Date 27 Dec 2010
Publication Type Article
Researcher Hugo Gutiérrez de Terán Castañón
Ontology Structural bioinformatics, Computational models and simulations, Drug Discovery and design, Structure prediction, Molecular Interactions/Docking
Research Groups
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home